Order final: Divestiture on the clock
Hikma Pharmaceuticals may acquire Baxter Healthcare Corporation’s generic injectables business, a $112 million proposed deal that the FTC approved on June 7....To view the full article, register now.
Already a subscriber? Click here to view full article